Recent RunsA run is one validator scoring cycle: a batch of papers is assigned, miners submit extractions, and the validator audits and scores the results.
58 stored validator runs for this network. Search or pick one to inspect below.
Run Result
run_20261009_094705_6ba33b
task_20261009_98981c648da9 · batch_20261009_18348f155dee · started Oct 09, 09:47 UTC
Run TimeElapsed validator time from run start to completion.
43m 10s
PapersPapers assigned to this batch.
1
Target MinersMiners selected for this batch.
2
ResponsesMiner response records received by the validator.
2
Scored MinersMiners with a final batch scoring receipt.
2
Run Overview
Production PathThe audit pipeline for this run, stage by stage. Use the tabs on the left to jump between Bronze, Miner Outputs, Validation, Comparison, Adjudication, Silver, Scores.
Inspect the run from reference output through miner comparison, adjudication, Silver, and scoring.
Runrun_20261009_094705_6ba33b
PaperThe selected paper slice shown in this run overview.openalex_w4413021696
Batch PapersPapers discovered for this validator batch.1
Graph CasesComparison and adjudication data loads when either graph stage is opened.On demand
Wall Time43m 10s
01
Bronze
Reference Miner / Bronze Artifact
Claims API Bronze artifact summary
Paperopenalex_w4413021696
Claims6
Evidence Items7
Claim C01Status: Supported
Sulfated polysaccharides, particularly fucoidan, provide broad-spectrum growth protection to E. coli isolates against multiple classes of antibiotics including beta-lactams, aminoglycosides, cephalosporins, and tetracycline, enhancing cell survival or maintaining growth at antibiotic concentrations at or above the minimum inhibitory concentration.
Qualifier & evidence
Qualifier: Demonstrated in E. coli strains DH5α and clinical isolates P09 and P58; tested at MIC levels of ampicillin, carbenicillin, piperacillin, kanamycin, cefoperazone, and tetracycline; polysaccharide concentrations typically 1 mg/ml; in vitro aerobic cultures in LB medium at 37°C. Untested for gram-positive bacteria, anaerobic gut commensals, or in the presence of mixed communities.
Evidence: EV01, EV02
EV01: E. coli DH5α growth protection from ampicillin by dietary supplements
Role: Metadata
Among 22 dietary supplements tested at 1 mg/ml against ampicillin (MIC: 3.75 μg/ml) in E. coli DH5α, ulvan polysaccharides (#P5) and fucoidan from Undaria pinnatifida (#P16) showed notable growth protection. Fucoidan-supplemented medium showed significantly smaller inhibition zones for kanamycin against E. coli P09 (p < 0.01, Student's t-test).
Quote: E. coli DH5α cell growth kinetics under ampicillin (MIC: 3.75 μg/ml), with 22 dietary supplements (1 mg/ml)
Source spans: span 3
EV02: Broad antibiotic class screen across E. coli strains
Role: Metadata
Comprehensive screen with 3 E. coli strains (DH5α, P09, P58), 38 dietary supplements, and 8 antibiotics. Protection by fucoidans and ulvan polysaccharide observed consistently across strains and antibiotic classes including beta-lactams, aminoglycosides, cephalosporins, and tetracycline.
Quote: we conducted a comprehensive screen with 3 E. coli strains (DH5α and two isolates from IBD patients, E. coli_P09 and E. coli_P58), a combination of 38 dietary supplements and 8 different antibiotics
Source spans: span 4
Claim C02Status: Supported
The ability of sulfated polysaccharides to protect bacteria from antibiotics is critically dependent on the polysaccharide's structural integrity, molecular weight, and sulfate content: higher molecular weight and higher degree of sulfation confer stronger protection, and desulfated or low-molecular-weight polysaccharides lack protective capacity.
Qualifier & evidence
Qualifier: Demonstrated using fucoidan fractions (<10 kDa vs >10 kDa), acid-hydrolyzed fucoidan, and modified dextrans with sulfur content 0-16% and molecular weight 5-500 kDa; tested against ampicillin and kanamycin on E. coli P09 and other isolates. The specific MW and sulfur thresholds may vary by polysaccharide type and antibiotic class.
Evidence: EV03
EV03: Molecular weight and sulfate dependency of protection
Role: Metadata
Fucoidan fractionation showed >10 kDa retentate retains protection while <10 kDa filtrate has no effect. Acid hydrolysis destroyed protective function. Dextran experiments: 16% sulfur + 500 kDa showed strongest protection; 40 kDa dextran required 15% sulfur for protection; sulfur-free dextrans showed no effect regardless of MW.
Quote: we found the dextran with 16% sulfur and 500 kDa exhibited the strongest protection against kanamycin on E. coli_P09
Source spans: span 5
Claim C03Status: Supported
Fucoidan itself has minimal direct impact on E. coli gene expression (inducing only 68 differentially expressed genes), yet it counteracts approximately 60% of the transcriptional changes induced by kanamycin, with 96.17% of the differentially expressed genes between kanamycin-plus-fucoidan and kanamycin-only treatments showing inverse fold-change relationships relative to kanamycin-versus-control comparisons.
Qualifier & evidence
Qualifier: Based on RNA-seq analysis of E. coli P09 cells cultured for 4-10 h at 37°C, comparing fucoidan-only (#P35), kanamycin-only, and kanamycin-plus-fucoidan (Kan_Fcdn) groups with q-value < 0.1 threshold using Sleuth differential expression analysis. The 59.9% reversal figure is specific to the kanamycin-fucoidan pair; other antibiotic-fucoidan combinations were not transcriptionally profiled.
Evidence: EV04
EV04: Transcriptomic reversal of kanamycin-induced gene expression by fucoidan
Role: Metadata
Kanamycin induced 1509 DEGs in E. coli P09; fucoidan alone induced only 68 DEGs. In the kanamycin-plus-fucoidan vs kanamycin comparison, 940 DEGs were identified, of which 904 (96.17%) overlapped with kanamycin-vs-control DEGs with inverse fold-change relationships. Overall, 59.9% of kanamycin-induced DEGs were reversed by fucoidan. Principal component analysis showed first component (68.2% variance) separated kanamycin-treated samples from others.
Quote: 59.9% (904/1509) of the kanamycin-induced DEGs are reversed by fucoidan
Source spans: span 6
EV05: MALDI-TOF MS evidence for fucoidan-kanamycin binding
Role: Metadata
In vitro mixing of fucoidan with kanamycin resulted in loss of the kanamycin signal in MALDI-TOF mass spectrometry, indicating direct molecular interaction. The mechanism is hypothesized to involve hydrogen bonding via sulfate ester groups, consistent with prior observations of fucoidan binding diverse molecules.
Quote: in vitro mixing of fucoidan with kanamycin results in loss of the kanamycin signal in MALDI-TOF MS, indicating a direct molecular interaction independent of cellular processes
Source spans: span 6
Claim C04Status: Partially Supported
Fucoidan binds directly to kanamycin in solution through non-specific molecular interactions, likely mediated by sulfate ester groups, inhibiting kanamycin's activity independent of bacterial cellular processes.
Qualifier & evidence
Qualifier: Supported by MALDI-TOF mass spectrometry showing loss of kanamycin signal upon in vitro mixing with fucoidan; additionally supported by the dependency of protection on sulfate content. The specific binding affinity, stoichiometry, and whether this binding mechanism extends to other antibiotic classes beyond kanamycin have not been directly measured. Surface plasmon resonance or similar biophysical measurements are needed to confirm binding kinetics.
Evidence: EV05
EV04: Transcriptomic reversal of kanamycin-induced gene expression by fucoidan
Role: Metadata
Kanamycin induced 1509 DEGs in E. coli P09; fucoidan alone induced only 68 DEGs. In the kanamycin-plus-fucoidan vs kanamycin comparison, 940 DEGs were identified, of which 904 (96.17%) overlapped with kanamycin-vs-control DEGs with inverse fold-change relationships. Overall, 59.9% of kanamycin-induced DEGs were reversed by fucoidan. Principal component analysis showed first component (68.2% variance) separated kanamycin-treated samples from others.
Quote: 59.9% (904/1509) of the kanamycin-induced DEGs are reversed by fucoidan
Source spans: span 6
EV05: MALDI-TOF MS evidence for fucoidan-kanamycin binding
Role: Metadata
In vitro mixing of fucoidan with kanamycin resulted in loss of the kanamycin signal in MALDI-TOF mass spectrometry, indicating direct molecular interaction. The mechanism is hypothesized to involve hydrogen bonding via sulfate ester groups, consistent with prior observations of fucoidan binding diverse molecules.
Quote: in vitro mixing of fucoidan with kanamycin results in loss of the kanamycin signal in MALDI-TOF MS, indicating a direct molecular interaction independent of cellular processes
Source spans: span 6
Claim C05Status: Supported
Fucoidan protects human gut microbial communities from antibiotic-induced disruption ex vivo, maintaining community composition and diversity profiles more similar to untreated controls than antibiotic-alone treatments do.
Qualifier & evidence
Qualifier: Demonstrated in anaerobic fecal microbial cultures from two human donors (H01, H02) treated with kanamycin (20 µg/ml) or ampicillin (5 µg/ml) and fucoidan #P35 (1 or 3 mg/ml). Community composition assessed via 16S rRNA amplicon sequencing with PERMANOVA and weighted UniFrac analyses. Protection was dose-dependent (3 mg/ml better than 1 mg/ml). Limited to two donors; broader human variability not assessed.
Evidence: EV06
EV06: Ex vivo human fecal community protection by fucoidan
Role: Metadata
Fucoidan supplementation (1-3 mg/ml) protected human fecal microbial communities from kanamycin (20 µg/ml) and ampicillin (5 µg/ml). Protected groups showed: higher cell densities at 24 h; maintained Prevotella abundance; community profiles more similar to controls; NMDS and weighted UniFrac confirmed clustering of fucoidan-treated groups closer to controls while antibiotic-only groups showed greater deviation. Donor H01 showed dose-dependent protection (3 mg/ml > 1 mg/ml).
Quote: Non-metric multidimensional scaling (NMDS) analysis and weighted UniFrac dissimilarity comparisons further confirmed distinct clustering by treatment groups, with the kanamycin group most noticeably deviating from the other four groups
Source spans: span 8
Claim C06Status: Supported
Dietary fucoidan facilitates the recovery of gut microbial communities in mice following antibiotic treatment, with fucoidan-treated groups showing community structure more closely resembling controls and exhibiting stronger post-treatment recovery of antibiotic-depleted bacterial taxa.
Qualifier & evidence
Qualifier: Demonstrated in C57BL/6J female mice (N=6 per group) administered kanamycin (1 mg/ml in drinking water, 6 h/day) with or without fucoidan-infused chow (5% w/w) over a 33-day study (pre-treatment, treatment days 2-17, recovery days 18-33). Community assessment by 16S rRNA amplicon sequencing of fecal pellets with DESeq2 analysis (qval < 0.01). Individual fucoidan and kanamycin consumption was not monitored, potentially introducing variable exposure levels between animals.
Evidence: EV07
EV07: In vivo mouse gut microbiota recovery by fucoidan
Role: Metadata
In C57BL/6J mice, dietary fucoidan (5% w/w) facilitated recovery of gut microbes after kanamycin treatment. The fucoidan group most strongly resembled controls in community structure (p < 0.001), followed by the FK group. A cluster of bacteria identified with fucoidan-enhanced recovery showed similar early-treatment decline irrespective of fucoidan, but less reduction by late treatment (d13+d17, p < 0.01) and significantly stronger post-treatment recovery (d27+d33, p < 0.01), with some taxa returning to baseline.
Quote: identified a cluster of bacteria that recovered after kanamycin treatment in the presence of fucoidan. their reduction was less pronounced in the FK group by the late treatment phase (d13 + d17, p < 0.01), and had a significantly stronger recovery during the post-treatment period (d27 + d33, p < 0.01), with some taxa even returning to baseline levels
Source spans: span 10
Overall Miner Ranking
Final batch scores and resulting validator weight allocation.
Miner's on-chain UID.
Mean across scoring-eligible papers. Miner misses count as zero; validator-failed papers are excluded for every miner.
How the miner entered this batch: qualification gives an unevaluated newcomer a seat, performance is sampled using prior scores, rotation prioritizes the oldest evaluation, and established fill completes any remaining seats.
Share of the paid miner pool, normalized across miners. Audit-only runs calculate it without submitting weights on-chain.
Share of the validator's full weight vector, including the owner burn allocation. Submitted only when the weight event succeeds.
Lowest single paper score, including zeros for missing papers.
Miner submissions out of scoring-eligible papers. Validator-failed papers are excluded from the denominator.
Papers this miner did not submit a score for.
Papers excluded neutrally for all miners because validator-side processing failed.
1
1
0.286
override
100.0%
10.0%
0.286
1/1
none
none
2
70
0.000
override
0.0%
0.0%
0.000
0/1
openale...21696
openale...21696
none
Per-Paper Scores
Search and compare paper results, or select a miner for its complete batch scorecard.
1 papers
All minersPaper-level batch summary
openale...21696
openalex_w4413021696
2/2
0
0.286
0.143
0.000
scored
Batch TopHighest final batch score.
0.286
Batch AvgAverage final batch score across scored miners.
0.143
WinnerHighest-ranked miner or tied miners for this batch.
UID 1
WeightsWhether the calculated validator weights were submitted on-chain.
